Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes
| Autor: | Katrina MacAulay, James R. Woodgett |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Clinical Biochemistry Pharmacology Article Substrate Specificity Glycogen Synthase Kinase 3 Insulin resistance GSK-3 Internal medicine Drug Discovery medicine Glucose homeostasis Humans Insulin Enzyme Inhibitors Glycogen synthase GSK3B biology Glucokinase medicine.disease Insulin receptor Endocrinology Diabetes Mellitus Type 2 biology.protein Molecular Medicine Insulin Resistance Signal Transduction |
| Zdroj: | Expert opinion on therapeutic targets. 12(10) |
| ISSN: | 1744-7631 |
| Popis: | Background: In spite of its rather specific name, glycogen synthase kinase-3 (GSK-3) is an eclectic cellular regulator that modulates an array of processes from nuclear transcription, to neurological functions and metabolism. The enzyme is also a focal point for diverse signaling pathways that act to suppress its activity. Objectives: To review recent evidence supporting the important role GSK-3 plays in glucose homeostasis and discuss the therapeutic potential of inhibiting this enzyme in the treatment of diabetes and insulin resistance. Results/conclusion: Despite its pleiotropic nature, GSK-3 has significant promise as a target for diabetes due to functional partitioning of the enzyme, tissue-selectivity and acute dosage-dependency of effects of inhibition, suggesting useful therapeutic windows. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|